Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ottmann

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentCornelius Miething, Rebekka Grundler, Claudia Mugler, et al.
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Acute lymphoblastic leukemiaDieter Hoelzer, Nicola Gökbuget, Oliver Ottmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA studyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Molecular Oncology|August 30, 2014
Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1Monika Raab, Andrea Krämer, Stephanie Hehlgans, et al.
Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2003
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588Philipp le Coutre, Karl-Anton Kreuzer, Stefan Pursche, et al.
Cancer|June 17, 2016
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Anna Czyz, Oliver Ottmann, et al.
Haematologica|May 25, 2010
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosisFelicitas Thol, Eva M Weissinger, Jürgen Krauter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentCornelius Miething, Rebekka Grundler, Claudia Mugler, et al.
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Hematology. American Society of Hematology. Education Program|November 26, 2002
Acute lymphoblastic leukemiaDieter Hoelzer, Nicola Gökbuget, Oliver Ottmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA studyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Molecular Oncology|August 30, 2014
Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1Monika Raab, Andrea Krämer, Stephanie Hehlgans, et al.
Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2003
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588Philipp le Coutre, Karl-Anton Kreuzer, Stefan Pursche, et al.
Cancer|June 17, 2016
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Anna Czyz, Oliver Ottmann, et al.
Haematologica|May 25, 2010
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosisFelicitas Thol, Eva M Weissinger, Jürgen Krauter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Pageof 6